Sugi Predict

Sugi Predict / Compounds / SCHEMBL9979655

SCHEMBL9979655

SCHEMBL9979655

CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(=O)O)[C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O

nearest known ligand 0.74

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ NPY2R P49146 10/20 0.69
▸ NPY1R P25929 10/20 0.69
▸ NPY4R P50391 8/20 0.69
▸ NPY5R Q15761 8/20 0.69
▸ GLP1R P43220 2/20 0.67
▸ CALCR P30988 3/20 0.67
▸ TFPI P10646 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4331434 0.90 NPY2R (0.75) NPY2RNPY1RNPY4RNPY5RCALCR
SCHEMBL238214 0.89 NPY2R (0.69) NPY2RNPY1RNPY4RNPY5RGLP1R
SCHEMBL30685550 0.89 NPY2R (0.70) NPY2RNPY1RNPY4RNPY5RGLP1R
Human Neuropeptide Y SCHEMBL29780330 0.89 NPY2R (0.79) NPY2RNPY1RNPY4RNPY5RCALCR
SCHEMBL30574247 0.89 NPY2R (0.74) NPY2RNPY1RNPY4RNPY5RCALCR
SCHEMBL30574250 0.89 NPY2R (0.72) NPY2RNPY1RNPY4RNPY5RCALCR
SCHEMBL30578733 0.89 CALCR (0.73) NPY2RNPY1RNPY4RNPY5RGLP1R
SCHEMBL30578729 0.89 CALCR (0.73) NPY2RNPY1RNPY4RNPY5RGLP1R
SCHEMBL30578734 0.89 CALCR (0.73) NPY2RNPY1RNPY4RNPY5RGLP1R
SCHEMBL15669203 0.89 NPY2R (0.74) NPY2RNPY1RNPY4RNPY5RGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220226431-A1 ANTI-ANGIOGENIC TREATMENT USING VLO4 WITH A BLOCKING PEPTIDE CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) 2022-07-21 — — US disclosed
US-11318184-B2 Anti-angiogenic treatment with a combination of antagonists CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC (US) 2022-05-03 — — US disclosed
US-20210169982-A1 COMBINATION THERAPY FOR INHIBITING SPROUT ANGIOGENESIS CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY LLC (US) 2021-06-10 — — US disclosed
US-10973877-B2 Compositions for inhibiting sprout angiogenesis CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) 2021-04-13 — — US disclosed
EP-3777877-A1 ADMINISTRATION OF AN ANTAGONIST OF ALPHA 5 BETA1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT California Northstate College Of Pharmacy, LLC (US) 2021-02-17 — — EP disclosed
US-20210000918-A1 COMPOSITIONS FOR INHIBITING SPROUT ANGIOGENESIS CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY LLC (US) 2021-01-07 — — US disclosed
US-20200397856-A1 ANTI-ANGIOGENIC TREATMENT WITH A COMBINATION OF ANTAGONISTS CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) 2020-12-24 — — US disclosed
EP-2793924-B1 ADMINISTRATION OF AN ANTAGONIST OF alpha 5 beta1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY LLC (US) 2020-11-04 — — EP disclosed
US-10786548-B2 Inhibiting sprout angiogenesis CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) 2020-09-29 — — US disclosed
US-10722555-B2 Anti-angiogenic treatment of endothelial tissue with a combination of antagonists CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC (US) 2020-07-28 — — US disclosed
US-20200069771-A1 INHIBITING SPROUT ANGIOGENESIS CALIFORNA NORTHSTATE COLLEGE OF PHARMACY LLC (US) 2020-03-05 — — US disclosed
US-20150105320-A1 ANTI-ANGIOGENIC TREATMENT OF OVARIAN, BREAST, AND PROSTATE CANCER WITH A COMBINATION OF ANTAGONISTS CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) 2015-04-16 — — US disclosed
US-8946159-B2 Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC (US) 2015-02-03 — — US disclosed
EP-2793924-A1 ADMINISTRATION OF AN ANTAGONIST OF alpha 5 beta1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT California Northstate College Of Pharmacy, LLC (US) 2014-10-29 — — EP disclosed
US-8815805-B2 Formulations having an antagonist of α5β1 for anti-angiogenesis and cancer treatment CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC (US) 2014-08-26 — — US disclosed
US-20130225495-A1 FORMULATIONS HAVING AN ANTAGONIST OF ALPHA 5 BETA 1 FOR ANTI-ANGIOGENESIS AND CANCER TREATMENT CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) 2013-08-29 — — US disclosed
US-20130225494-A1 FORMULATIONS HAVING AN ALPHA V BETA 3 ANTAGONIST AND AN ALPHA 2 BETA 1 ANTAGONIST FOR ANTI-ANGIONIC THERAPY CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) 2013-08-29 — — US disclosed
US-20130165380-A1 Administration of an antagonist of a5ß1 for anti-angiogenesis and cancer treatment CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC 2013-06-27 — — US disclosed
WO-2013096335-A1 ADMINISTRATION OF AN ANTAGONIST OF ALPHA 5 BETA 1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC (US) 2013-06-27 — — WO disclosed
US-20110319335-A1 COMBINED ADMINISTRATION OF INTEGRIN RECEPTOR ANTAGONISTS FOR ANTI-ANGIOGENIC THERAPY CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY 2011-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200069771-A1 INHIBITING SPROUT ANGIOGENESIS KDR, FLT4, FLT1 NPY2R 475/4885NPY1R 1578/4885NPY4R 1137/4885
US-20210169982-A1 COMBINATION THERAPY FOR INHIBITING SPROUT ANGIOGENESIS KDR, TEK, FLT4 NPY2R 288/4885NPY1R 1260/4885NPY4R 722/4885
US-20110319335-A1 COMBINED ADMINISTRATION OF INTEGRIN RECEPTOR ANTAGONISTS FOR ANTI-ANGIOGENIC THERAPY ITGA2, ITGB2, VCAM1 NPY2R 525/4885NPY1R 1772/4885NPY4R 1650/4885
US-20200397856-A1 ANTI-ANGIOGENIC TREATMENT WITH A COMBINATION OF ANTAGONISTS VCAM1, ITGA2, ITGB2 NPY2R 442/4885NPY1R 967/4885NPY4R 862/4885
US-20220226431-A1 ANTI-ANGIOGENIC TREATMENT USING VLO4 WITH A BLOCKING PEPTIDE VCAM1, ITGB2, ITGA2 NPY2R 259/4885NPY1R 683/4885NPY4R 501/4885
US-20210000918-A1 COMPOSITIONS FOR INHIBITING SPROUT ANGIOGENESIS KDR, TEK, VCAM1 NPY2R 472/4885NPY1R 1667/4885NPY4R 1365/4885
US-20130225495-A1 FORMULATIONS HAVING AN ANTAGONIST OF ALPHA 5 BETA 1 FOR ANTI-ANGIOGENESIS AND CANCER TREATMENT ITGB5, ITGA5, ITGB1 NPY2R 550/4885NPY1R 901/4885NPY4R 1074/4885
US-10973877-B2 Compositions for inhibiting sprout angiogenesis KDR, TEK, VCAM1 NPY2R 472/4885NPY1R 1667/4885NPY4R 1365/4885
US-20130225494-A1 FORMULATIONS HAVING AN ALPHA V BETA 3 ANTAGONIST AND AN ALPHA 2 BETA 1 ANTAGONIST FOR ANTI-ANGIONIC THERAPY VCAM1, ITGA2, ITGB2 NPY2R 674/4885NPY1R 1192/4885NPY4R 2197/4885
US-10786548-B2 Inhibiting sprout angiogenesis KDR, TEK, VCAM1 NPY2R 507/4885NPY1R 1598/4885NPY4R 1118/4885
US-11318184-B2 Anti-angiogenic treatment with a combination of antagonists VCAM1, ITGA2, ITGB2 NPY2R 442/4885NPY1R 967/4885NPY4R 862/4885
US-10722555-B2 Anti-angiogenic treatment of endothelial tissue with a combination of antagonists VCAM1, ITGA2, ITGB2 NPY2R 625/4885NPY1R 1375/4885NPY4R 1136/4885
US-20150105320-A1 ANTI-ANGIOGENIC TREATMENT OF OVARIAN, BREAST, AND PROSTATE CANCER WITH A COMBINATION OF ANTAGONISTS ITGB2, ITGA2, ITGB5 NPY2R 601/4885NPY1R 1354/4885NPY4R 1029/4885
US-20130165380-A1 Administration of an antagonist of a5ß1 for anti-angiogenesis and cancer treatment ANXA11, ANXA2, VCAM1 NPY2R 876/4885NPY1R 944/4885NPY4R 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.